GUTS vs. STIM, SMTI, ZIMV, RCEL, SNWV, NVRO, NYXH, ELMD, PDEX, and DRTS
Should you be buying Fractyl Health stock or one of its competitors? The main competitors of Fractyl Health include Neuronetics (STIM), Sanara MedTech (SMTI), ZimVie (ZIMV), AVITA Medical (RCEL), SANUWAVE Health (SNWV), Nevro (NVRO), Nyxoah (NYXH), Electromed (ELMD), Pro-Dex (PDEX), and Alpha Tau Medical (DRTS). These companies are all part of the "medical equipment" industry.
Fractyl Health vs.
Neuronetics (NASDAQ:STIM) and Fractyl Health (NASDAQ:GUTS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, media sentiment, community ranking, earnings and institutional ownership.
Neuronetics received 124 more outperform votes than Fractyl Health when rated by MarketBeat users. However, 100.00% of users gave Fractyl Health an outperform vote while only 68.62% of users gave Neuronetics an outperform vote.
Neuronetics has a beta of 1.97, suggesting that its share price is 97% more volatile than the S&P 500. Comparatively, Fractyl Health has a beta of 0.3, suggesting that its share price is 70% less volatile than the S&P 500.
Neuronetics has higher revenue and earnings than Fractyl Health. Neuronetics is trading at a lower price-to-earnings ratio than Fractyl Health, indicating that it is currently the more affordable of the two stocks.
In the previous week, Neuronetics and Neuronetics both had 2 articles in the media. Neuronetics' average media sentiment score of 0.98 beat Fractyl Health's score of 0.93 indicating that Neuronetics is being referred to more favorably in the media.
Neuronetics has a net margin of -50.09% compared to Fractyl Health's net margin of -64,849.48%. Fractyl Health's return on equity of 0.00% beat Neuronetics' return on equity.
53.6% of Neuronetics shares are held by institutional investors. 9.8% of Neuronetics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Neuronetics presently has a consensus price target of $5.50, suggesting a potential upside of 25.57%. Fractyl Health has a consensus price target of $11.00, suggesting a potential upside of 766.14%. Given Fractyl Health's stronger consensus rating and higher probable upside, analysts clearly believe Fractyl Health is more favorable than Neuronetics.
Summary
Neuronetics beats Fractyl Health on 10 of the 16 factors compared between the two stocks.
Get Fractyl Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for GUTS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fractyl Health Competitors List
Related Companies and Tools
This page (NASDAQ:GUTS) was last updated on 5/1/2025 by MarketBeat.com Staff
Buy GUTS Stock Free GUTS Stock Alerts